- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04646291
Retrospective Study on the Use, Efficiency, and Safety of the At-home Mosie Kit
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At-home intracervical insemination (ICI), folklorickly known as the "turkey-baster" method, has been used for decades to increase likelihood of pregnancy. This method works by depositing semen close to or at the cervix. While there are several devices such as over the counter syringes and silicone caps, the creator of the Mosie Baby syringe believes it is designed to be more ergonomic and compatible with a woman's body, easy and safe to use, and results in depositing the semen at or near the cervix opening. The Mosie Kit provides people with an at-home intracervical insemination option which could be used before resorting to more invasive and expensive options such as Intrauterine Insemination (IUI) or in vitro fertilization. There is vast evidence of Mosie's success in the form of happy users who have conceived. There is a desire to learn more about the safety, useability and experience of using the Mosie kit.
This retrospective study will examine the experience of people who have voluntarily chosen to purchase and use the Mosie Kit. The Mosie Kit consists of 2 syringes and a semen collection cup Understanding the safety, useability and experience of using the Mosie Kit will provide additional information about the nature of using intracervical insemination as a viable method for getting pregnant. The information gained will increase understanding of how viable the Mosie Kit is as a first step in trying to conceive and how it is perceived by the people who have chosen to use it.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78704
- Virtual Study - Online Data Collection
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Provide implicit consent by filling out and submitting the survey.
- Used a Mosie Kit to conceive during at least one cycle.
- At least 18 years old.
- Has an active email on file (presumed or they would not have received an invitation to participate. This information will not be verified as there is a desire to keep the survey completely anonymous.)
Exclusion Criteria:
- Never used a Mosie Kit
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Heterosexual Females with a Male partner
This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
|
The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
|
Females in LGBTQ Relationships
This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
|
The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
|
Solo parent
This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle.
However, it might also be a male who is using a surrogate female.
|
The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy Rate
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will measure whether using the Mosie Baby Kit for insemination will result in pregnancy.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Cycle in Which Pregnancy Was Reported
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The outcome measure is the number of cycles of Mosie use which resulted in a positive pregnancy test.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Pregnancy Rate Differences Between Couples With Fertility Issues and Without
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will measure the difference in pregnancy rates of Mosie Baby Kit users with known fertility issues and those without known fertility issues.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ease of Use
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will examine the perceived ease of use of the Mosie Kit.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Ease of Use: Usage Steps
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The use of the Mosie Kit requires several steps.
In order to examine ease of use, each step was also examined individually.
This table reports the data associated with each of use during each step of the insemination process.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Use of the Kit as Intended
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will examine whether the user's used the Mosie Kit as described in the instructions and as intended.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Perceived Safety of Using the Mosie Kit
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will examine the user's perceived safety of using the Mosie Kit syringe by evaluating overall perceived safety.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy Rate Comparison Between Male Infertility Source and Female Infertility Source or Unknown Infertility Status
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will examine the resulting pregnancy rates of users self-identified as having a male infertility issue versus those having a female infertility issue and those having no reported fertility issue.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Comparison of Pregnancy Rate Based on Known Fertility Issue
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study will examine the resulting pregnancy rates of users in comparison to the type of infertility issue reported.
|
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Insemination Schedule's Impact on Pregnancy
Time Frame: Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
The study examined pregnancy rates of users inseminating twice as expected as compared to using a different schedule. Four time points within each cycle were examined: 24-48 hours before ovulation, within 24 hours of ovulation, 24-48 hours after ovulation and 48 or more hours after ovulation. The recommended time frame is at least 2 insemination during the aggregate of 24-48 hours prior to ovulation and the within 24 hours of ovulation. The table below shows the data for how many women met the insemination criteria for each cycle that reported being pregnant. Note: Number of cycles reported by women vary from 1 cycle to 6 cycles. it is possible that a participant may have met the criteria at one cycle and not the other. Given this, the 3 arms when aggregated per row will equal the total of all participants. However, columns will not add up to the total participants per arm. |
Up to 6 full menstrual cycles (generally 28 days in length) prior to survey. The number of cycles reported by each participant may vary.
|
Effect of COVID on Family Expansion
Time Frame: Pregnancies reported as conceived using the Mosie Kit during the months of December 2019 to February 2020 (Pre-COVID) will be compared to those reported for March - July 2020 (during COVID).
|
The study will examine the effect of COVID on family expansion plans.
The analysis will be provided in aggregate because the focus is on the impact of COVID on family expansion overall and not on whether one arm has more or less impact.
This is a tertiary exploratory measure that does not evaluate the core product.
|
Pregnancies reported as conceived using the Mosie Kit during the months of December 2019 to February 2020 (Pre-COVID) will be compared to those reported for March - July 2020 (during COVID).
|
Pregnancy Outcomes During COVID
Time Frame: Pregnancies reported as conceived using the Mosie Kit during the months of September 2019 to February 2020 (Pre-COVID) will be compared to those reported for March - August 2020 (during COVID).
|
The study will examine whether there were more or less pregnancy rates during COVID.
This measure will be an aggregate measure of all women.
It is an exploratory measure to understand the impact of COVID.
No data will be provided by study arm.
|
Pregnancies reported as conceived using the Mosie Kit during the months of September 2019 to February 2020 (Pre-COVID) will be compared to those reported for March - August 2020 (during COVID).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karina Loyo, PhD MBA CCDM, Independent Researcher
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mosie-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Insemination with the Mosie Baby Kit
-
McGill University Health Centre/Research Institute...TerminatedInfertility | PregnancyCanada
-
Riverside Methodist HospitalPrevent Child Abuse AmericaCompleted
-
Okan UniversityCompletedPain, Procedural (During Sternum Dressing on Infants) | Physiological Parameters During Sternum Dressing in BabiesTurkey
-
Women and Infants Hospital of Rhode IslandTerminated
-
Xenios AGNot yet recruitingExtracorporeal Membrane Oxygenation | Cardiogenic Shock | ECLS | VA ECMOGermany
-
Ruhr University of BochumCompleted
-
University of YalovaCompletedTherapeutic Touch
-
Centre Hospitalier Sud FrancilienCentre National de Ressources de lutte contre la DouleurCompleted
-
HIV Prevention Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Division of...Enrolling by invitationHIV Infection | Sexually Transmitted Infections | Pre-exposure Prophylaxis | Systems NavigationMalawi